| Year |
Citation |
Score |
| 1987 |
Porter LH. An experimental investigation of the parietal lobes and temperature discrimination in monkeys. Brain Research. 412: 54-67. PMID 3607462 DOI: 10.1016/0006-8993(87)91439-9 |
0.401 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2021 |
Porter LH, Bakshi A, Pook D, Clark A, Clouston D, Kourambas J, Goode DL, Risbridger GP, Taylor RA, Lawrence MG. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. The Journal of Pathology. PMID 33620092 DOI: 10.1002/path.5652 |
0.058 |
|
| 2019 |
Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Science Translational Medicine. 11. PMID 30728288 DOI: 10.1126/Scitranslmed.Aau5758 |
0.056 |
|
| 2017 |
Porter LH, Hashimoto K, Lawrence MG, Pezaro C, Clouston D, Wang H, Papargiris M, Thorne H, Li J, Ryan A, Norden S, Moon D, Bolton DM, Sengupta S, et al. Intraductal carcinoma of the prostate can evade androgen-deprivation, with emergence of castrate tolerant cells. Bju International. PMID 28977728 DOI: 10.1111/bju.14043 |
0.052 |
|
| 2019 |
Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, et al. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. The Prostate. PMID 31212368 DOI: 10.1002/Pros.23839 |
0.051 |
|
| 2020 |
Lawrence MG, Porter LH, Clouston D, Murphy DG, Frydenberg M, Taylor RA, Risbridger GP. Knowing what's growing: Why ductal and intraductal prostate cancer matter. Science Translational Medicine. 12. PMID 32132214 DOI: 10.1126/scitranslmed.aaz0152 |
0.049 |
|
| 2021 |
Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, Pook D, Pezaro CJ, Sandhu S, Keerthikumar S, Quezada Urban R, Papargiris M, Kraska J, Madsen HB, Wang H, et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications. 12: 5049. PMID 34413304 DOI: 10.1038/s41467-021-25175-5 |
0.048 |
|
| 2018 |
Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, et al. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology. PMID 30049486 DOI: 10.1016/J.Eururo.2018.06.020 |
0.046 |
|
| 2015 |
Lawrence MG, Pook DW, Wang H, Porter LH, Frydenberg M, Kourambas J, Appu S, Poole C, Beardsley EK, Ryan A, Norden S, Papargiris MM, Risbridger GP, Taylor RA. Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. The Prostate. 75: 1475-83. PMID 26177841 DOI: 10.1002/pros.23039 |
0.045 |
|
| 2024 |
Brennen WN, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, Clark AK, Coleman IM, Dolgos R, Ferguson AM, Goode DL, Krutihof-de Julio M, Navone NM, Nelson PS, O'Neill E, ... Porter LH, et al. Defining the challenges and opportunities for using patient-derived models in prostate cancer research. The Prostate. PMID 38450798 DOI: 10.1002/pros.24682 |
0.042 |
|
| 2021 |
Lawrence MG, Porter LH, Choo N, Pook D, Grummet JP, Pezaro CJ, Sandhu S, Ramm S, Luu J, Bakshi A, Goode DL, Sanij E, Pearson RB, Hannan RD, Simpson KJ, et al. CX-5461 sensitises DNA damage repair proficient castrate-resistant prostate cancer to PARP inhibition. Molecular Cancer Therapeutics. PMID 34413130 DOI: 10.1158/1535-7163.MCT-20-0932 |
0.036 |
|
| 2023 |
Porter LH, Zhu JJ, Lister NL, Harrison SG, Keerthikumar S, Goode DL, Urban RQ, Byrne DJ, Azad A, Vela I, Hofman MS, Neeson PJ, Darcy PK, Trapani JA, Taylor RA, et al. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nature Communications. 14: 5346. PMID 37660083 DOI: 10.1038/s41467-023-40852-3 |
0.036 |
|
| 1993 |
Porter LH, Hecht GS, Sheaffer R. Disturbances in the performance of thermal discrimination tasks following cortical ablations in rats. Brain Research. 621: 319-30. PMID 8242345 DOI: 10.1016/0006-8993(93)90122-4 |
0.033 |
|
| 2023 |
Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, et al. The future of patient-derived xenografts in prostate cancer research. Nature Reviews. Urology. PMID 36650259 DOI: 10.1038/s41585-022-00706-x |
0.028 |
|
| 2021 |
Toivanen R, Porter LH, Li Z, Clouston D, Risbridger GP, Taylor RA. Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. Cancer Letters. PMID 34687792 DOI: 10.1016/j.canlet.2021.10.020 |
0.028 |
|
| 2017 |
Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. European Urology. PMID 28342640 DOI: 10.1016/j.eururo.2017.03.013 |
0.02 |
|
| Hide low-probability matches. |